[1]薛思军a,涂霁韬b.甲状腺乳头状癌组织中miR-137 水平表达及相关实验研究[J].现代检验医学杂志,2023,38(04):121-125.[doi:10.3969/j.issn.1671-7414.2023.04.022]
　XUE Sijuna,TU Jitaob.Expression of miR-137 in Papillary Thyroid Carcinoma Tissue and Its Related Experimental Study[J].Journal of Modern Laboratory Medicine,2023,38(04):121-125.[doi:10.3969/j.issn.1671-7414.2023.04.022]
点击复制

甲状腺乳头状癌组织中miR-137 水平表达及相关实验研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年04期
页码:
121-125
栏目:
论著
出版日期:
2023-07-15

文章信息/Info

Title:
Expression of miR-137 in Papillary Thyroid Carcinoma Tissue and Its Related Experimental Study
文章编号:
1671-7414（2023）04-121-05
作者:
薛思军a; 涂霁韬b
（黄石市中心医院/ 湖北理工学院附属医院a. 普通外科；b. 急诊科，湖北黄石 435000）
Author(s):
XUE Sijuna;  TU Jitaob
（a. Department of General Surgerg; b. Department of Emergency, Huangshi Central Hospital/ Affiliated Hospital of Hubei Polytechnic University, Hubei Huangshi 435000, China）
关键词:
甲状腺乳头状癌; 微小核糖核酸-137; 细胞增殖; 细胞侵袭
分类号:
R736.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.04.022
文献标志码:
A
摘要:
目的　探讨甲状腺乳头状癌（papillary thyroid carcinoma，PTC）组织中微小核糖核酸（microRNA，miR）-137表达变化，以及升高人PTC 细胞株TPC-1 中miR-137 表达对细胞生物学功能的影响。方法　收集2018 年4 月～ 2021年4 月黄石市中心医院普爱院区手术切除的121 例PTC 及配对癌旁组织，培养TPC-1 细胞并分为miR-137 模拟物组（M组）、阴性对照组（NC 组）和空白组（B 组），分别转染miR-137 模拟序列、转染阴性对照序列和仅加入转染试剂，逆转录定量PCR（qRT-PCR）法检测组织和细胞中miR-137 表达，MTT 法检测细胞增殖活性，Transwell 法检测细胞迁移和侵袭力。结果　PTC 组织中miR-137 水平（0.26±0.10）显著低于癌旁组织（0.42±0.18），差异有统计学意义（t=8.320，P<0.001）；与无包膜浸润、TNM 分期Ⅰ～Ⅱ和未发生淋巴结转移相比，包膜浸润、TNM 分期Ⅲ～Ⅳ和发生淋巴结转移PTC 组织中miR-137 水平降低，差异具有统计学意义（t=3.506，2.210，2.110，均P<0.05）；ROC 曲线分析结果显示，miR-137 水平在诊断PTC 时，曲线下面积是0.776（95% CI：0.717 ～ 0.835），当miR-137 表达量取0.35时，灵敏度和特异度分别为80.99%，65.29%；M 组细胞中miR-137 水平（2.30±0.19）高于NC 组（1.01±0.05）和B组（1.03±0.08），差异具有统计学意义（F=222.632，P<0.05），24，48，72 和96h 时增殖活性均低于NC 组和B 组（t=2.520 ～ 4.681，均P<0.05），迁移细胞数和侵袭细胞数均低于NC 组和B 组，差异具有统计学意义（t=7.316, 5.555;6.118, 8.078, 均P<0.05）。结论　miR-137 在PTC 组织中表达量降低，升高miR-137 水平可明显减少TPC-1 细胞增殖活性，抑制细胞迁移和侵袭。
Abstract:
Objective　To explore the changes of the expression of microRNA (miR)-137 in papillary thyroid carcinoma (PTC) tissues, and the effect of increasing the expression of miR-137 on the cell biological functions in human PTC cell line TPC- 1. Methods　A total of 121 cases of PTC and paired adjacent tissues surgically resected in Pu’ai Hospital Area of Huangshi Central Hospital were collected from April 2018 to April 2021. TPC-1 cells were cultured and divided into miR-137 mimic group (M group), negative control group (NC group) and blank group (B group), and which were transfected with miR-137 mimic sequence, negative control sequence and only adding transfection reagent, respectively. qRT-PCR method was used to detect the levels of miR-137 in tissues and cells, MTT method was used to detect cell proliferation activity, Transwell method was used to detect cell migration and invasiveness. Results　The level of miR-137 in PTC tissues was 0.26±0.10, which was significantly lower than 0.42±0.18 in the adjacent tissues, and the difference was statistically significant (t=8.320, P<0.001). Compared with patients with non-enveloped infiltration, TNM stage Ⅰ～Ⅱ and no lymph node metastasis, the levels of miR-137 in PTC tissues with enveloped infiltration, TNM stage Ⅲ～Ⅳ and lymph node metastasis were decreased (t=3.506，2.210，2.110，all P<0.05). The ROC curve analysis showed that the area under the curve was 0.776 (95% CI: 0.717 ～ 0.835) when the expression level of miR-137 was used to diagnose PTC. When the expression level of miR-137 was 0.35, the sensitivity and specificity was 80.99%，65.29%. The level of miR-137 in the M group was 2.30±0.19, which was higher than 1.01±0.05 in the NC group and 1.03±0.08 in the B group (F=222.632, P<0.05), the proliferation activities at 24, 48, 72 and 96h were lower than those in the NC group and the B group (t=2.520~4.681, all P<0.05), and the number of migrating cells and the number of invasive cells were lower than those in the NC group and the B group (t=37.316, 5.555; 6.118, 8.078, all P<0.05). Conclusion　The expression level of miR-137 in PTC tissues was reduced. Increasing the expression of miR-137 could significantly reduce the proliferation activity of TPC-1 cells and inhibit cell migration and invasion.

参考文献/References:

[1] 沈秋明, 王洁, 李卓颖, 等．上海市长宁区甲状腺癌发病率时间趋势分析[J]．中国公共卫生, 2021,37(4): 706-709. SHEN Qiuming, WANG Jie, LI Zhuoying, et al. Longterm incidence trend of thyroid cancer in Changning district of Shanghai, China, 1973-2013[J]. Chinese Journal of Public Health, 2021, 37(4): 706-709.
[2] RUIZ E M L, NIU Tianhua, ZERFAOUI M, et al. A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer[J]. Surgery, 2020, 167(1): 73-79.
[3] MATSUYAMA H, SUZUKI H I. Systems and synthetic microRNA biology: from biogenesis to disease pathogenesis[J]. International Journal of Molecular Sciences, 2019, 21(1): 132.
[4] 贺艳飞, 郭小旭, 姚培学, 等. 外泌体MicroRNA在部分肺部疾病中的研究进展[J]. 临床肺科杂志,2021, 26(4): 585-588. HE Yanfei, GUO Xiaoxu, YAO Peixue, et al. Research progress of exocrine microRNA in some pulmonary diseases[J]. Journal of Clinical Pulmonary Medicine, 2021, 26(4): 585-588.
[5] 谢青, 房延兵, 伊琳, 等.microRNA 与甲状腺乳头状癌相关性分析[J]. 中国生物制品学杂志, 2021,34(1): 48-53. XIE Qing, FANG Yanbing, YI Lin, et al. Correlation of microRNA to papillary thyroid carcinoma[J]. Chinese Journal of Biologicals, 2021, 34(1): 48-53.
[6] WANG Yajun, CHEN Riling, ZHOU Xia, et al. MiR-137: A novel therapeutic target for human glioma[J]. Molecular Therapy Nucleic Acids, 2020, 21: 614-622.
[7] 蔡冰玉, 慕长文．miR-137 在精神疾病和肿瘤中的研究进展[J]．河北医科大学学报, 2020, 41(8): 977-982. CAI Bingyu, MU Changwen. Research progress of miR-137 in mental diseases and tumors[J]. Journal of Hebei Medical University, 2020, 41(8): 977-982.
[8] 王东梅, 周茜, 霍煜廷, 等．甲状腺结节的影响因素研究进展[J]．中国普通外科杂志, 2018, 27(5): 635-641. WANG Dongmei, ZHOU Qian, HUO Yuting, et al. Research progress of influential factors for thyroid nodules[J]. Chinese Journal of General Surgery, 2018, 27(5): 635-641.
[9] DEHBI H M, MALLICK U, WADSLEY J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(1): 44-51.
[10] 彭继英, 杨红杰, 石晓欣, 等．细针穿刺细胞学检查在甲状腺癌碘-131 治疗后复发诊断中的应用价值[J]. 现代检验医学杂志, 2020, 35(1): 127-129. PENG Jiying, YANG Hongjie, SHI Xiaoxin, et al. Application value of fine needle aspiration cytology in recurrence diagnosis of thyroid cancer after iodine-131 treatment[J]. Journal of Modern Laboratory Medicine, 2020, 35(1): 127-129.
[11] 韩静, 魏建国, 高献争, 等．肺转移性甲状腺癌56例临床病理学特征及预后[J]. 中华病理学杂志,2021, 50(5): 505-507. HAN Jing, WEI Jianguo, GAO Xianzheng, et al. Clinicopathological features and prognosis of 56 small biopsy specimens of pulmonary metastatic thyroid carcinoma[J]. Chinese Journal of Pathology, 2021, 50(5): 505-507.
[12] 秦小静, 薛刚, 吴靖芳．微小RNA 在甲状腺乳头状癌中的作用及其研究现状[J]. 中国耳鼻咽喉颅底外科杂志, 2020, 26(3): 349-354. QIN Xiaojing, XUE Gang, WU Jingfang. Role and research progress of microRNA in papillary thyroid carcinoma[J]. Chinese Journal of Otorhinolaryngologyskull Base Surgery, 2020, 26(3): 349-354.
[13] 曹冉华, 呼群, 张国建．结直肠癌组织中miR-137,Notch1, DLL4 表达变化及意义[J]. 山东医药, 2020,60(1): 9-12. CAO Ranhua, HU Qun, ZHANG Guojian. Expression and significance of miR-137, Notch1 and DLL4 in colorectal cancer[J]. Shandong Medical Journal, 2020, 60(1): 9-12.
[14] DING Xiaoling, ZHANG Jie, FENG Ziqin, et al. MiR-137-3p inhibits colorectal cancer cell migration by regulating a KDM1A-dependent epithelialmesenchymal transition[J]. Digestive Diseases and Sciences, 2021, 66(7): 2272-2282.
[15] GUI Ying, WANG Lina, HUANG Zhihong. MiR-137 inhibits cervical cancer progression via downmodulating Notch1 and inhibiting the PI3K/AKT/mTOR signaling pathway[J]. Translational Cancer Research, 2021, 10(8): 3748-3756.
[16] 张长壮, 李定安, 王兵, 等．乳腺癌患者血清miR-137，miR-140 水平与临床病理特征及化疗疗效的相关性[J]. 中华内分泌外科杂志, 2022, 16(4): 492-496. ZHANG Changzhuang, LI Dingan, WANG Bing, et al. Correlation between serum miR-137 and miR-140 levels and clinicopathological features and efficacy of postoperative chemotherapy with ACT in patients with breast cancer[J]. Chinese Journal of Endocrine Surgery, 2022, 16(4): 492-496.
[17] CHEN Tengxiang, LEI Shan, ZENG Zhirui, et al. MicroRNA-137 suppresses the proliferation,migration and invasion of cholangiocarcinoma cells by targeting WNT2B[J]. International Journal of Molecular Medicine, 2020, 45(3): 886-896.
[18] HUANG Bin, HUANG Manping, LI Qin. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma[J]. Pathology Research and Practice, 2018, 214(12): 1980-1986.
[19] DING Xiaoling, ZHANG Jie, FENG Ziqin, et al. MiR-137-3p inhibits colorectal cancer cell migration by regulating a KDM1A-dependent epithelial–mesenchymal transition[J]. Digestive Diseases and Sciences, 2021, 66(7): 2272-2282.

相似文献/References:

[1]李桂荣,赵清侠a,宋 斌b,等.miR-221与miR-222在甲状腺乳头状癌组织中的表达及临床意义[J].现代检验医学杂志,2017,32(01):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
　LI Gui-rong,ZHAO Qing-xiaa,SONG Binb,et al.Expression of miR-221 and miR-222 in Papillary Thyroid Carcinoma Tissues and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(04):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
[2]孟凡萍,郝 坡,范 慧.甲状腺乳头状癌并发桥本氏甲状腺炎患者BRAF-V600E 基因表达及T 淋巴细胞亚群分析[J].现代检验医学杂志,2020,35(01):32.[doi:10.3969/j.issn.1671-7414.2020.01.009]
　MENG Fan-ping,HAO Po,FAN Hui.Expression of BRAF-V600E Gene and Analysis of Lymphocyte Subgroup in Thyroid Papillary Carcinoma Combined with Hashimoto's Thyroiditis[J].Journal of Modern Laboratory Medicine,2020,35(04):32.[doi:10.3969/j.issn.1671-7414.2020.01.009]
[3]王　玲,王　健,赵寅生,等.甲状腺乳头状癌患者血清促甲状腺激素水平和组织促甲状腺激素受体检测的临床应用价值[J].现代检验医学杂志,2021,36(01):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
　WANG Ling,WANG Jian,ZHAO Yin-sheng,et al.Clinical Application Value of Serum Thyrotropin Level and Tissue Thyrotropin Receptor Detection in Patients with Thyroid Papillary Carcinoma[J].Journal of Modern Laboratory Medicine,2021,36(04):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
[4]宋晓龙,宋 宇,魏 龙,等.血清TK1，TSH，TG，TGAb 检测联合TI RADS 分类在甲状腺乳头状癌早期筛查中的应用价值[J].现代检验医学杂志,2022,37(04):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
　SONG Xiao-long,SONG Yu,WEI Long,et al.Clinical Value of Serum TK1, TSH, TG and TGAb Detection Combined with TI-RADS Classification in Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(04):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
[5]宋晓龙,魏 龙,秦晋铝,等.甲状腺乳头状癌患者术前血清TK1 表达水平联合甲状腺超声特征构建中央区淋巴结转移预测模型及验证[J].现代检验医学杂志,2023,38(01):1.[doi:10.3969/j.issn.1671-7414.2023.01.001]
　SONG Xiao-long,WEI Long,QIN Jin-lü,et al.Construction and Validation of Prediction Model of Central Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma Based on Preoperative Serum TK1 Expression Level and Thyroid Ultrasound Features[J].Journal of Modern Laboratory Medicine,2023,38(04):1.[doi:10.3969/j.issn.1671-7414.2023.01.001]
[6]刘 星,霍占江.甲状腺乳头状癌组织中galecti-3 与miR-375 水平表达意义及相关性研究[J].现代检验医学杂志,2023,38(01):49.[doi:10.3969/j.issn.1671-7414.2023.01.010]
　LIU Xing,HUO Zhan-jiang.Expression Significance and Correlation of galectin-3 and miR-375 in Papillary Thyroid Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2023,38(04):49.[doi:10.3969/j.issn.1671-7414.2023.01.010]
[7]那将超,狄长安.甲状腺乳头状癌患者术后血清MMIF 和IL-6 表达水平与甲状旁腺功能减退持续时间的相关性研究[J].现代检验医学杂志,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
　NA Jiang-chao,DI Chang-an.Correlation between Postoperative Serum MMIF and IL-6 Expression Levels and Duration of Hypoparathyroidism in Patients with Papillary Thyroid Cancer[J].Journal of Modern Laboratory Medicine,2023,38(04):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
[8]周 钧a,汪庭军b,唐 珍a.甲状腺乳头状癌患者血清EGR1/2 mRNA 水平检测在临床早期实验诊断中的价值研究[J].现代检验医学杂志,2023,38(05):93.[doi:10.3969/j.issn.1671-7414.2023.05.018]
　ZHOU Juna,WANG Tingjunb,TANG Zhena.Value of Serum EGR1/2 mRNA Detection in Early Clinical Diagnosis of Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(04):93.[doi:10.3969/j.issn.1671-7414.2023.05.018]

备注/Memo

备注/Memo:
作者简介：薛思军（1978-），男，本科，主治医师，研究方向：普外科学，E-mail：xsjun6685@163.com。
通讯作者：涂霁韬（1978-），男，本科，主治医师，研究方向：急诊科学，E-mail：648995004@qq.com。
更新日期/Last Update: 2023-07-15